GleamWall
中文EN

CTSO Cytosorbents Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1175151 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.3%
TTM net income YoY-70.4%
TTM EPS YoY-205.0%
Revenue 3-yr CAGR0.3%
Net income 3-yr CAGR—

Margins

Gross margin72.9%
Operating margin-30.0%
Net margin-46.7%
FCF margin-18.7%
EBITDA margin-26.8%

Returns

ROE-521.5%
ROA-42.2%
ROIC (approx.)-39.8%
Asset turnover0.90x

Leverage & solvency

Liabilities / assets106.2%
Debt / equity—
Current ratio0.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-25.7%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.73M$9.63M$8.86M$9.23M$9.48M$9.62M$8.73M$9.15M
Cost of revenue$2.40M$2.58M$2.73M$2.43M$2.82M$2.80M$2.52M$2.90M
Gross profit$7.33M$7.05M$6.13M$6.80M$6.67M$6.81M$6.21M$6.25M
R&D expense$1.15M$1.45M$1.02M—$918,000$1.26M$1.66M—
SG&A expense$7.10M$7.96M$8.15M$9.44M$8.61M$9.17M$8.43M$7.63M
Operating income-$1.17M-$2.64M-$3.04M-$4.38M-$2.86M-$3.62M-$3.89M-$3.40M
Pretax income-$2.05M——-$5.50M-$3.57M—-$1.48M-$9.26M
Income tax$0$0$0$0-$401,000$0$0-$1.69M
Net income-$2.05M-$4.57M-$5.38M-$5.50M-$3.17M$1.95M-$1.48M-$7.57M
EBITDA-$869,000-$2.34M-$2.75M-$4.09M-$1.96M-$3.31M-$3.58M-$3.24M
EPS (basic)-0.65-1.46-1.72—-1.010.03-0.02—
EPS (diluted)-0.65-1.46-1.72—-1.010.03-0.02—
Weighted avg. shares (diluted)3.15M62.81M62.74M—3.14M67.17M60.73M—
Balance sheet
Cash & equivalents$4.21M$4.41M$4.81M$6.25M$7.54M$10.20M$13.11M$9.76M
Receivables$7.07M$6.79M$7.15M$7.55M$7.43M$7.74M$7.67M$7.32M
Inventory$3.23M$3.69M$4.48M$5.28M$4.00M$3.71M$3.02M$2.73M
Current assets$15.44M$15.74M$17.76M$20.63M$21.31M$22.99M$25.41M$21.60M
PP&E, net$6.89M$7.17M$7.51M$7.82M$8.19M$8.47M$8.72M$9.00M
Intangibles$2.80M$2.86M$2.95M$3.23M$3.59M$3.74M$3.70M$3.72M
Total assets$37.16M$37.96M$40.56M$44.18M$45.75M$47.99M$50.78M$47.37M
Current liabilities$28.03M$24.02M$16.30M$9.71M$10.11M$9.84M$9.74M$9.82M
Short-term debt$17.52M$14.15M$6.65M—————
Long-term debt$17.52M$3.09M$10.31M$16.67M$14.57M$14.38M$14.19M$14.00M
Total debt$35.05M$17.24M$16.96M$16.67M$14.57M$14.38M$14.19M$14.00M
Total liabilities$39.47M$38.71M$38.37M$38.28M$36.73M$36.40M$36.24M$36.27M
Shareholders' equity-$2.31M-$751,000$2.19M$5.90M$9.02M$11.59M$14.54M$11.11M
Net debt$30.84M$12.83M$12.15M$10.42M$7.03M$4.17M$1.08M$4.23M
Shares outstanding3.15M62.84M62.73M3.14M62.79M62.61M62.53M54.83M
Cash flow statement
Operating cash flow-$267,000-$583,000-$1.16M-$4.83M-$2.58M-$1.51M-$3.47M-$2.34M
Capital expenditure$20,000$14,000$11,000$108,000$17,000$36,879$2,000$69,343
Free cash flow-$287,000-$597,000-$1.17M-$4.93M-$2.59M-$1.55M-$3.47M-$2.41M
Investing cash flow-$4,000$7,000-$46,000-$291,000$55,000-$131,758-$47,000-$124,000
Financing cash flow———$2.48M$0-$1,134$6.83M$167,000
Depreciation & amortization$300,000$300,000$289,000$295,000$900,000$300,000$306,000$154,000
Stock-based compensation$291,000$368,000$544,000$886,000$488,000$571,000$818,000$920,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.